Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Starkey

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
British Journal of Cancer|June 18, 2020
Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?Oliver J Pickles, Lennard Y W Lee, Thomas Starkey, et al.
Journal of Leukocyte Biology|June 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trialCarmela De Santo, Aimee Jackson, Francis Mussai, et al.
Nature Immunology|October 30, 2020
Author Correction: A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signalsPhilippos Demetriou, Enas Abu-Shah, Salvatore Valvo, et al.
Nature Immunology|September 15, 2020
A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signalsPhilippos Demetriou, Enas Abu-Shah, Salvatore Valvo, et al.
International Journal of Cancer|March 10, 2025
Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2 infection: The COV-SPOT initiativeNathan Appanna, Rosie Mew, Sophie Williams, et al.
Cancer Cell|July 31, 2020
Utility of COVID-19 Screening in Cancer PatientsLennard Y W Lee, Thomas Hill, Oliver Topping, et al.
Lancet (London, England)|June 1, 2020
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyLennard Yw Lee, Jean-Baptiste Cazier, Vasileios Angelis, et al.
The Lancet. Oncology|August 28, 2020
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyLennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, et al.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based studyLennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|June 18, 2020
Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?Oliver J Pickles, Lennard Y W Lee, Thomas Starkey, et al.
Journal of Leukocyte Biology|June 18, 2026
The anti-CD33 antibody drug conjugate gemtuzumab ozogamicin depletes and functionally resets CD33+ myeloid-derived suppressor cells in patients with metastatic cancer: a phase II single arm, open label trialCarmela De Santo, Aimee Jackson, Francis Mussai, et al.
Nature Immunology|October 30, 2020
Author Correction: A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signalsPhilippos Demetriou, Enas Abu-Shah, Salvatore Valvo, et al.
Nature Immunology|September 15, 2020
A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signalsPhilippos Demetriou, Enas Abu-Shah, Salvatore Valvo, et al.
International Journal of Cancer|March 10, 2025
Safe prescribing in cancer patients during the COVID-19 pandemic and outcomes following restart of cancer care following SARS-CoV-2 infection: The COV-SPOT initiativeNathan Appanna, Rosie Mew, Sophie Williams, et al.
Cancer Cell|July 31, 2020
Utility of COVID-19 Screening in Cancer PatientsLennard Y W Lee, Thomas Hill, Oliver Topping, et al.
Lancet (London, England)|June 1, 2020
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyLennard Yw Lee, Jean-Baptiste Cazier, Vasileios Angelis, et al.
The Lancet. Oncology|August 28, 2020
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort studyLennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, et al.
The Lancet. Oncology|May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyLennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based studyLennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
Pageof 3